First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020

“…OPALO. The objective of this phase II single-arm trial is to assess the efficacy and safety of first-line therapy with panitumumab plus FOLFIRI in older patients (≥ 70 years) with wildtype RAS and wild-type BRAF mCRC [46]. Only patients with a performance status of 0-1 and no more than one comorbidity will be included.…”